ClinicalTrials.gg
CompletedNCT01393626Updated Apr 28, 2017Results posted

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

A Phase 2 interventional study of Placebo and CP-690,550 in Crohn's Disease, sponsored by Pfizer. Completed at 140 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-28.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.

Enrollment
2nd of 11
280 · median 180
Started
2011
with 2 others
Phase 2
9 of 17
none open now
Registered
7th of 17
by date

Among the 17 studies in Crohn Disease by Pfizer, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2011, is one of 9 in phase 2, and was the 7th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Crohn Disease by Pfizer as a file.
02

Study summary

This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is more effective than placebo (inactive drug).

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between the ages of 18 and 75 years at screening (upper age limit will be 64 years in India and 65 years in the Netherlands).
  • Subjects with clinical diagnosis of Crohn's disease for at least 6 months prior to screening.
  • Subjects with active moderate to severe ileal, ileocolic, or colonic CD defined by a baseline score of Crohn's Disease Activity Index (CDAI) of 220 to 450 at baseline.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC.
  • Subjects diagnosed with Crohn's disease but without previous exposure to treatment (i.e., treatment-naïve).
  • Subjects receiving the following treatment for Crohn's disease:
  • Azathioprine, 6-mercaptopurine or methotrexate within 2 weeks prior to baseline.
  • Anti-TNFα therapy within 8 weeks prior to baseline.
  • Interferon therapy within 8 weeks prior to baseline.
  • Cyclosporine, mycophenolate, or tacrolimus within 4 weeks prior to baseline.
  • Intravenous within 2 weeks prior to baseline.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
280 participants (actual)

Study arms

  • Placebo comparator
    Placebo BID

    Drug: Placebo

  • Experimental
    5mg BID

    Drug: CP-690,550

  • Experimental
    10mg BID

    Drug: CP-690,550

Interventions

  • DrugPlacebo

    oral tablets twice daily

  • oral tablets twice daily

  • oral tablets twice daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Clinical Remission (as Defined by a Crohn's Disease Activity Index [CDAI] Score of Less Than [<] 150 Points) at Week 8

    Clinical remission was a CDAI \< 150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants in Clinical Remission (CDAI <150) at Weeks 2 and 4

    Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

    Time frame: Weeks 2 and 4

  2. Percentage of Participants Achieving Clinical Response-70 (as Defined by a Decrease in CDAI Score of at Least 70 Points From Baseline) at Weeks 2, 4, and 8

    Clinical response-70 was defined as a reduction in CDAI score from baseline of at least 70 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

    Time frame: Baseline, Weeks 2, 4, and 8

  3. Percentage of Participants Achieving Clinical Response-100 (as Defined by a Decrease in CDAI Score of at Least 100 Points From Baseline) at Weeks 2, 4, and 8

    Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

    Time frame: Baseline, Weeks 2, 4, and 8

  4. Percentage of Participants Achieving Either Clinical Response-100 or Clinical Remission (CDAI<150) at Weeks 2, 4, and 8

    Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. Clinical remission was a CDAI \< 150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

    Time frame: Baseline, Weeks 2, 4, and 8

  5. CDAI Scores at Weeks 2, 4, and 8

    CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Weeks 2, 4, and 8

  6. C-Reactive Protein (CRP) Serum Concentrations at Weeks 2, 4, and 8

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Time frame: Weeks 2, 4, and 8

  7. Calprotectin Fecal Concentrations at Weeks 2, 4, and 8

    Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.

    Time frame: Weeks 2, 4, and 8

  8. Tofacitinib Plasma Concentrations From 0 to 2 Hours Post Dose on Day 1 and at Week 8/Early Termination (ET) Visit

    Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.

    Time frame: Pre-dose, 20 minutes, 40 minutes, 1 hour, and 2 to 3 hours post-dose on Day 1 and Week 8/ET visit

  9. Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 8/ET Visit

    The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QOL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.

    Time frame: Baseline, Week 8/ET visit

  10. Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 8/ET Visit Using Analysis of Covariance (ANCOVA)

    IBDQ is a validated PRO instrument for measuring QOL in IBD consisting of 32 items scored from 1 (worst response) to 7 (best response). 32 items are grouped into 4 domains scored as follows: bowel symptoms 10 - 70; systemic symptoms 5 - 35; emotional function 12 - 84; social function 5 - 35. For each domain, higher score indicates better QOL. Total score is the sum of each item score, \& ranged from 32 to 224 with a higher score indicating better QOL. Positive change in total score indicated improvement in QOL. Adjusted means were derived from an ANCOVA model with baseline value as covariate, treatment group \& prior use of anti-tumor necrosis factor (TNF) alpha (α) treatments as factors. The 15 mg BID treatment group was closed to further enrolment early in the study by Protocol Amendment 5 after only 16 participants were enrolled in this group. Therefore, the efficacy analysis was not performed for this group as the results may be difficult to interpret due to the small sample size.

    Time frame: Baseline, Week 8/ET visit

  11. Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 8/ET Visit

    The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.

    Time frame: Week 8/ET visit

  12. Percentage of Participants With ≥16 Point Increase From Baseline in IBDQ Total Score at Week 8/ET Visit

    The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.

    Time frame: Week 8/ET visit

  13. Percentage of Participants With a Response to the Patient-Reported Treatment Impact Assessment (PRTI) at Week 8/ET Visit by Category

    The IBD Patient Reported Treatment Impact Modified (PRTI) questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to re-use the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.

    Time frame: Week 8/ET visit

  14. Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 8/ET Visit

    The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL.

    Time frame: Baseline, Week 8/ET visit

  15. Change From Baseline SF-36 Component and Domain Scores at Week 8/ET Visit Using ANCOVA

    The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group and prior use of anti-TNF alpha treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

    Time frame: Baseline, Week 8/ET visit

  16. EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 8/ET Visit

    EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from -0.594 to 1.000; a higher score indicates a better health state.

    Time frame: Baseline, Week 8/ET visit

  17. Change From Baseline EQ-5D Utility Scores at Week 8/ET Visit Using ANCOVA

    EQ-5D is a participant rated questionnaire to assess health-related QoL via a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain \& discomfort, anxiety \& depression; 1 = better health state (no problems); 3 = worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed to a total score ranging from -0.594 to 1.000; higher score indicates better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group \& prior use of anti-TNFα treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

    Time frame: Baseline, Week 8/ET visit

  18. EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit

    EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline, Week 8/ET visit

  19. Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit Using ANCOVA

    EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group \& prior use of anti-TNF alpha treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

    Time frame: Baseline, Week 8/ET visit

07

Results

Posted Apr 28, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Started91868616
Completed73747415
Not completed1812121
Withdrew: Adverse event2150
Withdrew: Did not meet entrance criteria1000
Withdrew: Lack of efficacy6641
Withdrew: Lost to follow-up1110
Withdrew: Withdrawal by subject6400
Withdrew: Other1000
Withdrew: Protocol violation1020

Outcome measures

PrimaryPercentage of Participants in Clinical Remission (as Defined by a Crohn's Disease Activity Index [CDAI] Score of Less Than [<] 150 Points) at Week 8

Clinical remission was a CDAI \< 150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants in Clinical Remission (as Defined by a Crohn's Disease Activity Index [CDAI] Score of Less Than [<] 150 Points) at Week 8
Percentage of ParticipantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Percentage of Participants in Clinical Remission (as Defined by a Crohn's Disease Activity Index [CDAI] Score of Less Than [<] 150 Points) at Week 836.67 (26.75 to 47.49)43.53 (32.80 to 54.72)43.02 (32.39 to 54.15)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Cochran-Mantel-Haenszel · p = 0.3249 · Mean difference (final values): 6.86 · 95% CI -7.64 to 21.36
  • Placebo vs Tofacitinib 10 mg BID · Cochran-Mantel-Haenszel · p = 0.3916 · Mean difference (final values): 6.36 · 95% CI -8.09 to 20.80
SecondaryPercentage of Participants in Clinical Remission (CDAI <150) at Weeks 2 and 4

Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

Time frame:
Weeks 2 and 4
Reported as:
Number · Percentage of Participants
Percentage of Participants in Clinical Remission (CDAI <150) at Weeks 2 and 4
Percentage of ParticipantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 210.00 (4.68 to 18.14)9.41 (4.15 to 17.71)9.30 (4.10 to 17.51)
Week 421.11 (13.21 to 30.99)24.71 (15.99 to 35.25)22.09 (13.86 to 32.33)
SecondaryPercentage of Participants Achieving Clinical Response-70 (as Defined by a Decrease in CDAI Score of at Least 70 Points From Baseline) at Weeks 2, 4, and 8

Clinical response-70 was defined as a reduction in CDAI score from baseline of at least 70 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Clinical Response-70 (as Defined by a Decrease in CDAI Score of at Least 70 Points From Baseline) at Weeks 2, 4, and 8
Percentage of ParticipantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 237.78 (27.77 to 48.62)47.06 (36.13 to 58.19)44.19 (33.48 to 55.30)
Week 450.00 (39.27 to 60.73)57.65 (46.45 to 68.30)56.98 (45.85 to 67.61)
Week 862.22 (51.38 to 72.23)76.47 (66.03 to 85.00)74.42 (63.87 to 83.22)
SecondaryPercentage of Participants Achieving Clinical Response-100 (as Defined by a Decrease in CDAI Score of at Least 100 Points From Baseline) at Weeks 2, 4, and 8

Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Clinical Response-100 (as Defined by a Decrease in CDAI Score of at Least 100 Points From Baseline) at Weeks 2, 4, and 8
Percentage of ParticipantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 223.33 (15.06 to 33.43)34.12 (24.18 to 45.20)32.56 (22.84 to 43.52)
Week 437.78 (27.77 to 48.62)48.24 (37.26 to 59.34)45.35 (34.58 to 56.45)
Week 854.44 (43.60 to 64.98)70.59 (59.71 to 79.98)68.60 (57.70 to 78.19)
SecondaryPercentage of Participants Achieving Either Clinical Response-100 or Clinical Remission (CDAI<150) at Weeks 2, 4, and 8

Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. Clinical remission was a CDAI \< 150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Either Clinical Response-100 or Clinical Remission (CDAI<150) at Weeks 2, 4, and 8
Percentage of ParticipantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 224.44 (16.00 to 34.64)34.12 (24.18 to 45.20)32.56 (22.84 to 43.52)
Week 438.89 (28.79 to 49.74)49.41 (38.39 to 60.48)46.51 (35.68 to 57.59)
Week 855.56 (44.70 to 66.04)71.76 (60.96 to 81.00)69.77 (58.92 to 79.21)
SecondaryCDAI Scores at Weeks 2, 4, and 8

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Weeks 2, 4, and 8
Reported as:
Mean · Score on a scale
CDAI Scores at Weeks 2, 4, and 8
Score on a scalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Week 2 (n=85, 78, 77, 16)258.04 ± 89.79237.60 ± 67.87241.21 ± 75.27270.31 ± 90.78
Week 4 (n=81, 78, 71, 15)228.65 ± 102.01213.38 ± 86.04203.58 ± 86.69228.27 ± 103.01
Week 8 (n=80, 77, 75, 15)194.90 ± 111.88162.77 ± 87.67159.08 ± 81.30172.47 ± 119.28
SecondaryC-Reactive Protein (CRP) Serum Concentrations at Weeks 2, 4, and 8

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Time frame:
Weeks 2, 4, and 8
Reported as:
Mean · Milligrams per liter (mg/L)
C-Reactive Protein (CRP) Serum Concentrations at Weeks 2, 4, and 8
Milligrams per liter (mg/L)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Week 2 (n=89, 84, 81, 16)17.28 ± 23.078.26 ± 11.408.56 ± 14.037.89 ± 9.42
Week 4 (n=83, 82, 78, 16)18.94 ± 31.268.17 ± 10.609.48 ± 21.3510.33 ± 16.80
Week 8 (n=80, 77, 74, 15)18.12 ± 26.429.49 ± 15.336.55 ± 11.005.77 ± 7.74
SecondaryCalprotectin Fecal Concentrations at Weeks 2, 4, and 8

Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.

Time frame:
Weeks 2, 4, and 8
Reported as:
Mean · mg per kilogram (mg/kg)
Calprotectin Fecal Concentrations at Weeks 2, 4, and 8
mg per kilogram (mg/kg)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Week 2 (n=81, 76, 73, 16)492.95 ± 664.51384.81 ± 342.90403.35 ± 352.57455.10 ± 461.87
Week 4 (n=81, 82, 71, 16)493.26 ± 682.81467.09 ± 377.65359.30 ± 306.88338.11 ± 391.65
Week 8 (n=75, 66, 72, 14)428.45 ± 479.36417.70 ± 336.75385.66 ± 316.71349.61 ± 365.37
SecondaryTofacitinib Plasma Concentrations From 0 to 2 Hours Post Dose on Day 1 and at Week 8/Early Termination (ET) Visit

Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.

Time frame:
Pre-dose, 20 minutes, 40 minutes, 1 hour, and 2 to 3 hours post-dose on Day 1 and Week 8/ET visit
Reported as:
Mean · nanograms per milliliter
Tofacitinib Plasma Concentrations From 0 to 2 Hours Post Dose on Day 1 and at Week 8/Early Termination (ET) Visit
nanograms per milliliterTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Day 1, 0 hours (n=83, 83, 16)0.006687 ± 0.0491441.193 ± 9.0312NA ± NA
Day 1, 20 minutes (n=82, 83, 16)27.44 ± 27.33562.28 ± 60.79565.83 ± 63.232
Day 1, 40 minutes (n=82, 81, 16)41.03 ± 24.21084.61 ± 47.470151.4 ± 61.288
Day 1, 1 hour (n=83, 83, 16)41.22 ± 18.43282.48 ± 40.782149.9 ± 42.220
Day 1, 2 hours (n=83, 82, 16)31.85 ± 12.44270.01 ± 24.838106.1 ± 26.661
Week 8/ET, 0 hours (n=78, 72, 13)4.216 ± 7.108911.57 ± 21.45323.89 ± 45.837
Week 8/ET, 20 minutes (n=70, 70, 12)25.89 ± 21.48571.14 ± 54.969127.6 ± 89.861
Week 8/ET, 40 minutes (n=70, 69, 12)37.75 ± 23.89193.09 ± 46.471148.7 ± 58.948
Week 8/ET, 1 hour (n=70, 69, 12)37.47 ± 21.38483.14 ± 35.100144.7 ± 48.137
Week 8/ET, 2 hours (n=72, 70, 13)27.61 ± 15.74262.38 ± 27.50592.03 ± 27.806
SecondaryInflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 8/ET Visit

The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QOL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.

Time frame:
Baseline, Week 8/ET visit
Reported as:
Mean · Score on a scale
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 8/ET Visit
Score on a scalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
IBDQ Total Score, Baseline118.50 ± 28.48117.89 ± 27.98113.67 ± 28.45124.19 ± 26.97
IBDQ Total Score, Week 8/ET144.99 ± 37.97159.14 ± 35.39156.64 ± 36.66159.00 ± 47.98
Bowel Function Score, Baseline37.78 ± 8.1737.39 ± 9.3736.29 ± 7.7237.50 ± 9.78
Bowel Function Score, Week 8/ET45.76 ± 12.1950.94 ± 11.0250.69 ± 11.0252.50 ± 13.81
Emotional Status Score, Baseline45.88 ± 13.0445.34 ± 13.2744.55 ± 13.2747.25 ± 10.41
Emotional Status Score, Week 8/ET56.31 ± 14.3959.54 ± 13.7858.32 ± 14.7157.25 ± 20.07
Systemic Symptoms Score, Baseline15.22 ± 5.2415.58 ± 4.3614.60 ± 4.7816.44 ± 5.35
Systemic Symptoms Score, Week 8/ET19.70 ± 6.5122.24 ± 6.3021.80 ± 6.2722.88 ± 7.05
Social Function Score, Baseline19.62 ± 7.2819.48 ± 6.6218.23 ± 7.0923.00 ± 6.29
Social Function Score, Week 8/ET23.23 ± 8.4726.43 ± 7.5725.83 ± 7.8026.38 ± 9.58
SecondaryChange From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 8/ET Visit Using Analysis of Covariance (ANCOVA)

IBDQ is a validated PRO instrument for measuring QOL in IBD consisting of 32 items scored from 1 (worst response) to 7 (best response). 32 items are grouped into 4 domains scored as follows: bowel symptoms 10 - 70; systemic symptoms 5 - 35; emotional function 12 - 84; social function 5 - 35. For each domain, higher score indicates better QOL. Total score is the sum of each item score, \& ranged from 32 to 224 with a higher score indicating better QOL. Positive change in total score indicated improvement in QOL. Adjusted means were derived from an ANCOVA model with baseline value as covariate, treatment group \& prior use of anti-tumor necrosis factor (TNF) alpha (α) treatments as factors. The 15 mg BID treatment group was closed to further enrolment early in the study by Protocol Amendment 5 after only 16 participants were enrolled in this group. Therefore, the efficacy analysis was not performed for this group as the results may be difficult to interpret due to the small sample size.

Time frame:
Baseline, Week 8/ET visit
Reported as:
Mean · Score on a scale
Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 8/ET Visit Using Analysis of Covariance (ANCOVA)
Score on a scalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
IBDQ Total Score26.58 ± 3.7641.20 ± 3.9040.05 ± 3.90
Bowel Function Score8.36 ± 1.2313.76 ± 1.2813.88 ± 1.28
Emotional Status Score10.33 ± 1.3713.87 ± 1.4212.54 ± 1.43
Systemic Symptoms Score4.41 ± 0.666.70 ± 0.696.68 ± 0.69
Social Function Score3.68 ± 0.797.03 ± 0.826.95 ± 0.82
SecondaryPercentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 8/ET Visit

The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.

Time frame:
Week 8/ET visit
Reported as:
Number · Percentage of Participants
Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 8/ET Visit
Percentage of ParticipantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 8/ET Visit26.145.243.243.8
SecondaryPercentage of Participants With ≥16 Point Increase From Baseline in IBDQ Total Score at Week 8/ET Visit

The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.

Time frame:
Week 8/ET visit
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥16 Point Increase From Baseline in IBDQ Total Score at Week 8/ET Visit
Percentage of ParticipantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Percentage of Participants With ≥16 Point Increase From Baseline in IBDQ Total Score at Week 8/ET Visit61.475.076.575.0
SecondaryPercentage of Participants With a Response to the Patient-Reported Treatment Impact Assessment (PRTI) at Week 8/ET Visit by Category

The IBD Patient Reported Treatment Impact Modified (PRTI) questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to re-use the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.

Time frame:
Week 8/ET visit
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Response to the Patient-Reported Treatment Impact Assessment (PRTI) at Week 8/ET Visit by Category
Percentage of ParticipantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
PSA: Extremely dissatisfied17.06.07.46.3
PSA: Dissatisfied10.29.66.20
PSA: Neither satisfied nor dissatisfied25.019.316.025.0
PSA: Satisfied40.945.843.225.0
PSA: Extremely satisfied6.819.327.243.8
PPTA: Injectable prescription medicines42.039.522.237.5
PPTA: Prescription medicines taken by mouth37.544.456.843.8
PPTA: Surgery2.32.500
PPTA:Prescription medicines and surgery5.77.48.66.3
PPTA: No treatment12.56.212.312.5
PPA: Definitely prefer the drug I am receiving now33.042.248.156.3
PPA: Slight preference for drug I'm receiving now19.327.722.225.0
PPA: I have no preference either way28.419.313.618.8
PPA: Slight preference for previous treatment9.12.47.40
PPA: No, I definitely prefer my previous treatment10.28.48.60
PWA: Would definitely want to use same drug again44.353.061.750.0
PWA: Might want to use the same drug again11.424.117.337.5
PWA: I am not sure20.510.88.66.3
PWA: Might not want to use same drug again6.82.44.90
PWA: Definitely not want to use same drug again17.09.67.46.3
SecondaryShort Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 8/ET Visit

The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL.

Time frame:
Baseline, Week 8/ET visit
Reported as:
Mean · Score on a Scale
Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 8/ET Visit
Score on a ScalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Physical component score, Baseline37.12 ± 7.6638.49 ± 6.7835.28 ± 8.4937.09 ± 9.14
Physical component score, Week 8/ET40.84 ± 9.2345.23 ± 8.8544.29 ± 9.4147.01 ± 7.97
Mental Component Score, Baseline36.50 ± 12.2634.85 ± 11.6835.84 ± 10.6839.26 ± 11.85
Mental Component Score, Week 8/ET42.46 ± 11.2143.69 ± 12.1543.65 ± 11.8742.73 ± 16.37
Physical Functioning Domain, Baseline43.73 ± 8.9343.56 ± 8.8141.36 ± 10.0342.66 ± 9.04
Physical Functioning Domain, Week 8/ET46.55 ± 8.9349.68 ± 8.4348.37 ± 8.7849.57 ± 8.99
Role Physical Domain, Baseline35.34 ± 9.9436.36 ± 9.7132.57 ± 10.9237.68 ± 12.43
Role Physical Domain, Week 8/ET39.92 ± 10.6444.49 ± 11.5242.84 ± 11.5944.39 ± 13.18
Bodily Pain Domain, Baseline34.69 ± 8.7935.22 ± 8.4433.32 ± 8.2534.98 ± 8.23
Bodily Pain Domain, Week 8/ET40.81 ± 10.4344.68 ± 11.2945.10 ± 10.4147.61 ± 11.21
General Health Domain, Baseline30.58 ± 7.2131.37 ± 7.1529.56 ± 7.5232.08 ± 12.42
General Health Domain, Week 8/ET34.36 ± 8.5036.79 ± 8.5337.19 ± 10.7537.98 ± 13.51
Vitality Domain, Baseline35.06 ± 9.7034.66 ± 7.8635.80 ± 9.0537.55 ± 11.88
Vitality Domain, Week 8/ET41.20 ± 11.4545.22 ± 11.9444.60 ± 12.5348.77 ± 13.41
Social Functioning Domain, Baseline34.71 ± 11.8335.53 ± 11.6933.83 ± 11.3635.90 ± 10.61
Social Functioning Domain, Week 8/ET40.02 ± 12.3345.01 ± 11.7943.46 ± 11.4343.63 ± 14.94
Role Emotional Domain, Baseline38.45 ± 13.9837.20 ± 12.9635.34 ± 13.2339.12 ± 14.02
Role Emotional Domain, Week 8/ET43.06 ± 12.4344.77 ± 12.4643.76 ± 11.9442.90 ± 16.58
Mental Health Domain, Baseline37.60 ± 12.3035.95 ± 11.3836.98 ± 11.0941.27 ± 10.27
Mental Health Domain, Week 8/ET43.75 ± 11.0243.58 ± 11.6744.76 ± 11.6443.00 ± 15.96
SecondaryChange From Baseline SF-36 Component and Domain Scores at Week 8/ET Visit Using ANCOVA

The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group and prior use of anti-TNF alpha treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

Time frame:
Baseline, Week 8/ET visit
Reported as:
Mean · Score on a Scale
Change From Baseline SF-36 Component and Domain Scores at Week 8/ET Visit Using ANCOVA
Score on a ScalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Physical component score3.72 ± 0.9277.28 ± 0.9678.07 ± 0.956
Mental Component Score6.47 ± 1.1437.88 ± 1.1787.13 ± 1.180
Physical Functioning Domain3.01 ± 0.8506.14 ± 0.8765.59 ± 0.876
Role Physical Domain5.02 ± 1.1528.76 ± 1.1918.95 ± 1.183
Bodily Pain Domain6.41 ± 1.1329.94 ± 1.17411.10 ± 1.171
General Health Domain3.62 ± 0.8975.55 ± 0.9377.03 ± 0.933
Vitality Domain5.55 ± 1.1909.84 ± 1.2258.05 ± 1.233
Social Functioning Domain5.25 ± 1.1639.72 ± 1.2068.66 ± 1.204
Role Emotional Domain5.59 ± 1.2227.28 ± 1.2577.14 ± 1.260
Mental Health Domain6.46 ± 1.1007.05 ± 1.1367.41 ± 1.134
SecondaryEuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 8/ET Visit

EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from -0.594 to 1.000; a higher score indicates a better health state.

Time frame:
Baseline, Week 8/ET visit
Reported as:
Mean · Score on a Scale
EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 8/ET Visit
Score on a ScalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Utility Score, Baseline0.56 ± 0.290.58 ± 0.260.49 ± 0.310.61 ± 0.24
Utility Score, Week 8/ET0.64 ± 0.270.71 ± 0.280.71 ± 0.270.77 ± 0.30
SecondaryChange From Baseline EQ-5D Utility Scores at Week 8/ET Visit Using ANCOVA

EQ-5D is a participant rated questionnaire to assess health-related QoL via a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain \& discomfort, anxiety \& depression; 1 = better health state (no problems); 3 = worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed to a total score ranging from -0.594 to 1.000; higher score indicates better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group \& prior use of anti-TNFα treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

Time frame:
Baseline, Week 8/ET visit
Reported as:
Mean · Score on a Scale
Change From Baseline EQ-5D Utility Scores at Week 8/ET Visit Using ANCOVA
Score on a ScalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Change From Baseline EQ-5D Utility Scores at Week 8/ET Visit Using ANCOVA0.08 ± 0.0290.14 ± 0.0300.16 ± 0.030
SecondaryEQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit

EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline, Week 8/ET visit
Reported as:
Mean · mm
EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit
mmPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
VAS Score, Baseline46.83 ± 18.6349.51 ± 18.0342.74 ± 18.0452.06 ± 24.11
VAS Score, Week 8/ET58.32 ± 21.3167.07 ± 19.3965.77 ± 19.7169.81 ± 21.11
SecondaryChange From Baseline EQ-5D VAS Scores at Week 8/ET Visit Using ANCOVA

EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group \& prior use of anti-TNF alpha treatments as factors. The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.

Time frame:
Baseline, Week 8/ET visit
Reported as:
Mean · mm
Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit Using ANCOVA
mmPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit Using ANCOVA11.97 ± 2.16619.56 ± 2.25220.62 ± 2.222

Adverse events

Collected over SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment (i.e. 11 weeks). Non-SAEs were recorded from time of first dose of study treatment through last participant visit (i.e. 15 weeks).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/91 (3.3%)43/91 (47.3%)
Tofacitinib 5 mg BID—3/86 (3.5%)37/86 (43%)
Tofacitinib 10 mg BID—10/86 (11.6%)42/86 (48.8%)
Tofacitinib 15 mg BID—0/16 (0%)9/16 (56.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Crohn's diseaseGastrointestinal disorders1/910/863/860/16
Anal fistulaGastrointestinal disorders0/910/861/860/16
Small intestinal obstructionGastrointestinal disorders0/911/861/860/16
Abdominal abscessInfections and infestations0/911/860/860/16
Anal abscessInfections and infestations0/910/861/860/16
GastroenteritisInfections and infestations0/911/860/860/16
Pneumonia influenzalInfections and infestations0/910/861/860/16
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/910/861/860/16
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/910/861/860/16
AnxietyPsychiatric disorders0/910/861/860/16
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BID
Urinary tract infectionInfections and infestations5/911/862/864/16
DiarrhoeaGastrointestinal disorders3/911/860/863/16
Abdominal painGastrointestinal disorders5/913/867/862/16
HeadacheNervous system disorders7/918/865/861/16
NauseaGastrointestinal disorders8/915/867/860/16
NasopharyngitisInfections and infestations3/913/866/860/16
Crohn's diseaseGastrointestinal disorders6/915/864/861/16
LymphadenopathyBlood and lymphatic system disorders0/910/860/861/16
BradycardiaCardiac disorders0/910/860/861/16
Ear painEar and labyrinth disorders0/910/861/861/16

Baseline characteristics

Safety analysis set - included all participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BIDTotal
Mean37.2 ± 11.740.2 ± 11.539.3 ± 13.741.3 ± 14.339.0 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTofacitinib 15 mg BIDTotal
Female6032477146
Male3154399133
08

Study locations

140 sites
  • ACRI - Phase 1, LLC
    Anaheim, California 92801, United States
  • Advanced Clinical Research Institute - Phase 1, LLC
    Anaheim, California 92801, United States
  • AGMG Endoscopy Center
    Anaheim, California 92801, United States
  • Alliance Clinical Research
    Oceanside, California 92056, United States
  • Alliance Clinical Research, LLC
    Poway, California 92064, United States
  • Sharp Rees-Stealy Medical Group, Inc.
    San Diego, California 92101, United States
  • Sharp Rees-Stealy Medical Group, Inc.
    San Diego, California 92123, United States
  • Clinical Research Of The Rockies
    Lafayette, Colorado 80026, United States
  • Endoscopy Center of the Rockies - Longmont
    Longmont, Colorado 80501, United States
  • Endoscopy Center of Connecticut, LLC
    Guilford, Connecticut 06437, United States
  • Endoscopy Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Gastroenterology Center of Connecticut, PC
    Hamden, Connecticut 06518, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Metropolitan Gastroenterology Group, PC
    Washington, District of Columbia 20006, United States
  • Gasteroenterology Consultants of Clearwater
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy Center
    Clearwater, Florida 33756, United States
  • Clinical Research of West Florida, Inc
    Clearwater, Florida 33765, United States
  • Citrus Surgery & Endoscopy Center (Colonoscopy & Biopsy Only)
    Crystal River, Florida 34429, United States
  • Shands Endoscopy Center
    Gainesville, Florida 32608, United States
  • Shands Hospital at the University of Florida
    Gainesville, Florida 32610-0214, United States
  • Investigational Drug Service
    Gainesville, Florida 32610, United States
  • Shands Medical Plaza and Cancer Center
    Gainesville, Florida 32610, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Suncoast Endoscopy Center (Colonoscopy Only)
    Inverness, Florida 34453, United States
  • FQL Research, LLC
    Miramar, Florida 33025, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Gulfshore Endoscopy Center (Endoscopies Only)
    Naples, Florida 34102, United States
  • North Florida Gastroenterology Research, LLC
    Orange Park, Florida 32073, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • Southwest Gastroenterology
    Oak Lawn, Illinois 60453, United States
  • Heartland Medical Research, Inc (Administrative Only)
    Clive, Iowa 50325, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • Iowa Endoscopy Center (Colonoscopy Only)
    Clive, Iowa 50325, United States
  • Iowa Radiology (MRI, X-Ray Only)
    Clive, Iowa 50325, United States
  • Cotton-O'Neil Clinical (X-Ray)
    Topeka, Kansas 66606, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • Stormont-Vail MRI Center of Kansas
    Topeka, Kansas 66606, United States
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • Chevy Chase Endoscopy Center
    Chevy Chase, Maryland 20815, United States
  • Metropolitan Gastroenterology Group, PC
    Chevy Chase, Maryland 20815, United States
  • East Ann Arbor Health and Geriatrics Center
    Ann Arbor, Michigan 48109-2701, United States
  • University of Michigan Health Systems
    Ann Arbor, Michigan 48109-5000, United States
  • Clinical Research Institute of Michigan LLC
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • NYU Langone Nassau Gastroenterology Associates
    Great Neck, New York 11021, United States
  • Premier Medical Group of the Hudson Valley, PC
    Poughkeepsie, New York 12601, United States
  • Charlotte Gastroenterology and Hepatology, PLLC
    Charlotte, North Carolina 28207, United States
  • Charlotte Radiology (Chest X-Ray Only)
    Charlotte, North Carolina 28211, United States
  • University Hospitals Chagrin Highlands Health Center
    Beachwood, Ohio 44122, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Dayton Gastroenterology, Inc.
    Dayton, Ohio 45415, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • The Endoscopy Center of Lake County
    Mentor, Ohio 44060, United States
  • University Hospitals Westlake Medical Center
    Westlake, Ohio 44145, United States
  • Great Lakes Gastroenterology
    Willoughby, Ohio 44094, United States
  • Regional Gastroenterology Associates of Lancaster, Ltd.
    Lancaster, Pennsylvania 17604, United States
  • UT Health Science Center
    Houston, Texas 77030, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Cardiology Consultants (ECG Site Only)
    Norfolk, Virginia 23502, United States
  • Digestive and Liver Disease Specialists
    Norfolk, Virginia 23502, United States
  • MRI & CT Diagnostics
    Virginia Beach, Virginia 23455, United States
  • The Center for Digestive Health
    Milwaukee, Wisconsin 53215, United States
  • Wisconsin Center for Advanced Research - GI Associates, LLC
    Milwaukee, Wisconsin 53215, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
  • Medical Diagnostic Imaging (MDI) X-ray and MRI only
    Milwaukee, Wisconsin 53222, United States
  • Allegiance Research Specialists
    Wauwatosa, Wisconsin 53226, United States
  • GI Associates
    Wauwatosa, Wisconsin 53226, United States
  • Nepean Public Hospital
    Kingswood, New South Wales 2747, Australia
  • Monash Medical Center
    Clayton, Victoria 3168, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • AKH Wien Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • 4-MBAL, Parvo vatreshno otdelenie
    Sofia, 1000, Bulgaria
  • MBAL Sveti Ivan Rilski, Klinika po Gastroenterologia
    Sofia, 1431, Bulgaria
  • MBAL Voennomeditsinska Akademia
    Sofia, 1606, Bulgaria
  • MBAL Sofiamed OOD, Otdelenie po gastroenterologia
    Sofia, 1797, Bulgaria
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • Office of Dr. David C. Pearson
    Victoria, British Columbia V8R 6R3, Canada
  • Office of Drs. Ranjith Andrew Singh and Jamie D. Papp
    Victoria, British Columbia V8V 3P9, Canada
  • PerCuro Clinical Research Ltd.
    Victoria, British Columbia V8V 3P9, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Montreal General Hospital - McGill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
  • Inflammatory Bowel Disease Centre, Montreal General Hospital, McGill University Health Centre
    Montreal, Quebec H3G1A4, Canada
  • University Hospital Centre Rijeka
    Rijeka, 51000, Croatia
  • University Hospital Center Zagreb
    Zagreb, 10000, Croatia
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Kralove, 50012, Czech Republic
  • RDG centrum s.r.o.
    Hradec Kralove, 50012, Czech Republic
  • Medial Pharma spol.s.r.o.
    Hradec Králové, 500 12, Czech Republic
  • Hopital Huriez, CHRU de Lille
    Lille Cedex, 59037, France
  • Hopital Haut-Leveque
    Pessac, 33064, France
  • Hopital Robert Debre
    Reims cedex, 51092, France
  • Charite - Campus Berlin Mitte
    Berlin, 10117, Germany
  • Charite Universitaetsmedizin Berlin, Campus Benjamin Franklin
    Berlin, 12203, Germany

Showing the first 100 of 140 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Panes J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16. PubMed 28209624 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 13, 2011
Start
Oct 2011
Primary completionActual
Feb 2015
CompletionActual
Mar 2015
Results first posted
Apr 28, 2017
Last update
Apr 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01393626
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Oct 2011
Primary completion
Feb 2015
Completion
Mar 2015
Results posted
Apr 28, 2017
Last update
Apr 28, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion